Plain-English translation of NCT06637267 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This research study is testing a new blood test called Proclarix to see if it can better help doctors decide which men need a prostate biopsy. Right now, doctors use a blood test called PSA to screen for prostate cancer, but it isn't always accurate—some men get biopsies even when they don't have cancer. The study will compare the Proclarix test results with PSA levels and MRI scans to see if this medication can predict cancer more accurately and help avoid unnecessary biopsies.
Many men get prostate biopsies based on PSA results alone, even though most don't actually have cancer. Biopsies can cause uncomfortable side effects like infection and bleeding. This trial exists to see if the new blood test can be more accurate, so doctors can spare men from unnecessary procedures while still catching real cancer early.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have a blood sample collected (about 40 milliliters, or roughly 3 tablespoons) at Cantonal Hospital Aarau. This happens alongside your already-scheduled MRI scan and biopsy as part of your normal care. Your blood sample will be tested with the new Proclarix test and compared with your imaging results and biopsy findings to see if the new test is better at predicting which cancers are serious.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Switzerland